• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Teligent, Inc. to Hold Conference Call for Second Quarter 2021 Financial Results on Monday, August 16, 2021

    8/11/21 4:05:00 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care
    Get the next $TLGT alert in real time by email

    BUENA, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Monday, August 16th, 2021 to discuss the second quarter ended June 30, 2021 financial results and business update.

    Conference Call Information

    Date: Monday, August 16, 2021

    Time: 8:30 a.m. Eastern Time

    Dial-in numbers: Toll Free: 877-407-0792 International: 201-689-8263

    Conference ID: 13721972

    This call is available via webcast and can be accessed under News & Events in the Investor Relations section of Teligent, Inc.'s website at www.teligent.com.

    About Teligent, Inc.

    Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.

    Forward-Looking Statements

    This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as "plan," "believe," "continue," "should" or words of similar meaning. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to successfully complete future product acquisitions. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in Teligent, Inc.'s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports we file with the Securities and Exchange Commission. Teligent, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

    Contact:

    Philip Yachmetz

    Teligent, Inc.

    (856) 776-4632

    [email protected]

    www.teligent.com 



    Primary Logo

    Get the next $TLGT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLGT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TLGT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Benesch Joseph

    3 - Teligent, Inc. (0000352998) (Issuer)

    10/8/21 4:31:06 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form 3 filed by new insider Lozynski Alyssa

    3 - Teligent, Inc. (0000352998) (Issuer)

    10/7/21 11:09:36 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Celentano John E

    4 - Teligent, Inc. (0000352998) (Issuer)

    7/22/21 5:04:00 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teligent to Pursue Asset Sale through Voluntary Chapter 11 Process

    BUENA, N.J., Oct. 14, 2021 /PRNewswire/ -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company ("Teligent" or the "Company"), today announced that the Company has, together with certain of its affiliates, filed for voluntary protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware to pursue a sale process that is intended to maximize the value of the Company. The Company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several interested parties. The Company expects to consummate a sale of the entire busi

    10/14/21 6:15:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update

    –Update on FDA Inspection of Buena Facility–Assessing New Growth Opportunities in Injectables–Conference Call to Be Held on August 16, 2021 at 8:30 am Eastern Standard Time –Dial in: (877) 407-0792 US Toll Free Number  (201) 689-8263 International Number  Confirmation Number: 13721972 BUENA, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the second quarter of 2021 and provided a business update. "Product demand in our core business was impacted by a combination of factors, including remediation-related activities, the ongoing effects of the COVID-19 pandemic, and modest ge

    8/16/21 7:00:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. to Hold Conference Call for Second Quarter 2021 Financial Results on Monday, August 16, 2021

    BUENA, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Monday, August 16th, 2021 to discuss the second quarter ended June 30, 2021 financial results and business update. Conference Call InformationDate: Monday, August 16, 2021Time: 8:30 a.m. Eastern TimeDial-in numbers: Toll Free: 877-407-0792 International: 201-689-8263Conference ID: 13721972 This call is available via webcast and can be accessed under News & Events in the Investor Relations section of Teligent, Inc.'s website at www.teligent.com. About Teligent, Inc.T

    8/11/21 4:05:00 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    SEC Filings

    View All

    SEC Form 25-NSE filed by Teligent, Inc.

    25-NSE - Teligent, Inc. (0000352998) (Subject)

    10/27/21 9:46:36 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Teligent, Inc. (0000352998) (Filer)

    10/15/21 4:35:51 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. filed SEC Form 8-K: Leadership Update

    8-K - Teligent, Inc. (0000352998) (Filer)

    9/27/21 5:02:29 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    Leadership Updates

    Live Leadership Updates

    View All

    Teligent Announces Hiring of Chief Financial Officer

    BUENA, N.J., April 15, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT) ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced the hiring and appointment of Ernest R. De Paolantonio as Chief Financial Officer of the Company, effective April 15, 2021. Timothy B. Sawyer, President and CEO of the Company, commented, "We are very pleased that Ernie has agreed to join our Teligent team. Over the last several months, we have made key additions to our leadership team, and the appointment of Ernie to the CFO position reflects our commitment to bring in highly talented and experienced individuals who have a strong track record of success. E

    4/15/21 7:30:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. Announces Appointment of Carter Pate to Board of Directors

    BUENA, N.J., Feb. 23, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed Carter Pate to its Board of Directors, effective immediately. Mr. Pate will serve on the Audit and Nominating and Corporate Governance Committees. Mr. Pate leads a family-owned investment firm and serves on the Board of Directors at multiple companies, including Global Step and Advanced Emissions Solutions, Inc. He excels at leading companies through moments of change to drive business objectives and redefine their possibilities for growth.    John Celentano, Chairman of Teligent's Board of Dire

    2/23/21 7:30:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. Announces Appointment of William S. Marth to Board of Directors

    BUENA, N.J., Feb. 16, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed industry veteran William S. Marth to its Board of Directors, effective immediately. Mr. Marth brings over 25 years of expertise and a proven track record of leading companies in the generic pharmaceutical and contract manufacturing industries. John Celentano, Chairman of Teligent's Board of Directors, commented on the appointment, stating that "We are excited to have Bill join Teligent's Board of Directors. He is a strategic leader with extensive experience in helping businesses transform and

    2/16/21 7:30:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    Financials

    Live finance-specific insights

    View All

    Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update

    –Update on FDA Inspection of Buena Facility–Assessing New Growth Opportunities in Injectables–Conference Call to Be Held on August 16, 2021 at 8:30 am Eastern Standard Time –Dial in: (877) 407-0792 US Toll Free Number  (201) 689-8263 International Number  Confirmation Number: 13721972 BUENA, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the second quarter of 2021 and provided a business update. "Product demand in our core business was impacted by a combination of factors, including remediation-related activities, the ongoing effects of the COVID-19 pandemic, and modest ge

    8/16/21 7:00:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. to Hold Conference Call for Second Quarter 2021 Financial Results on Monday, August 16, 2021

    BUENA, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Monday, August 16th, 2021 to discuss the second quarter ended June 30, 2021 financial results and business update. Conference Call InformationDate: Monday, August 16, 2021Time: 8:30 a.m. Eastern TimeDial-in numbers: Toll Free: 877-407-0792 International: 201-689-8263Conference ID: 13721972 This call is available via webcast and can be accessed under News & Events in the Investor Relations section of Teligent, Inc.'s website at www.teligent.com. About Teligent, Inc.T

    8/11/21 4:05:00 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. Announces First Quarter 2021 Earnings Report and Provides Business Update

    –Continued Remediation Progress Being Made–Reiterating Prior Guidance of Informing FDA on Inspection Readiness During 3Q2021–Conference Call to Be Held on May 25, 2021 at 4:30 pm Eastern Standard Time –Dial in: (800) 708-4540 US Toll Free Number  (847) 619-6397 US Number  Confirmation Number: 50161966 BUENA, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the first quarter of 2021 and provided a business update. "As we prepare for the second half of 2021, we are pleased with the progress being made with respect to remediation, our strengthened capital position, and the recent

    5/25/21 7:00:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - Teligent, Inc. (0000352998) (Subject)

    2/16/21 4:30:32 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Teligent, Inc. (0000352998) (Subject)

    2/16/21 12:02:06 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G filed

    SC 13G - Teligent, Inc. (0000352998) (Subject)

    2/16/21 10:39:59 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care